| Code | CSB-RA891782MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of OTSA-101-DTPA-⁹⁰Y, targeting FZD10 (Frizzled-10)—a 7-transmembrane Wnt signaling receptor in the frizzled family. FZD10 has been reported to be highly overexpressed in synovial sarcoma (SS) while showing little to no expression in most normal adult tissues (with limited exceptions such as placenta), making it an attractive tumor-associated surface target for antigen profiling and target-engagement studies.
OTSA-101-DTPA-⁹⁰Y is a radioimmunoconjugate in which the anti-FZD10 monoclonal antibody OTSA-101 is chelator-conjugated (e.g., DTPA) and labeled with yttrium-90 to deliver β-radiation selectively to FZD10-expressing lesions; related clinical studies have also used ¹¹¹In-labeled OTSA-101 for biodistribution/uptake assessment. This biosimilar provides the antibody component alone, enabling researchers to investigate FZD10 biology, cell-surface binding, and target-mediated internalization/trafficking independent of radiotoxicity, and to support assay development or custom conjugation workflows (e.g., chelator coupling for imaging/therapy research).
There are currently no reviews for this product.